EUVIMEDEUVIMED entdecken
Klinische Studie

Kynurenine pathway metabolites predict antianhedonic effects of electroconvulsive therapy in patients with treatment-resistant depression

Qing-Bin Zeng, Xing-Bing Huang, Rui Xu, De-Wei Shang, Shan-Qing Huang, Xiong Huang, Xin-Hu Yang, Lloyd Balbuena, Yu-Tao Xiang, Wei Zheng

Journal of Affective Disorders · 2025-06 · 379 · 764-771

DOI: 10.1016/j.jad.2025.03.041 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Affective Disorders, 2025-06. Verfasst von Qing-Bin Zeng und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China; Key Laboratory of Neurogenetics and Channelopathies of Guangdong Provi…. Hauptthemen laut MEDLINE: Electroconvulsive Therapy, Kynurenine, Depressive Disorder, Treatment-Resistant, Anhedonia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Program key projects, Guangzhou Municipal Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Electroconvulsive therapy (ECT) is a rapid and effective antianhedonic treatment for treatment-resistant depression (TRD). Whether this effect is related to kynurenine (KYN) pathway metabolites lacks evidence, so we examined if the changes in these metabolites can serve as potential biomarkers for the antianhedonic effects of ECT. METHODS: In this single-arm clinical trial, sixty patients diagnosed with TRD received a series of eight ECT treatments and provided blood samples. Antianhedonic effects were measured by items 1 (apparent sadness), 2 (reported sadness), 6 (concentration difficulties), 7 (lassitude) and 8 (inability to feel) of the Montgomery-Åsberg Depression Rating Scale (MADRS). Serum tryptophan (TRP), KYN, kynurenic acid (KYNA) concentration, KYN/TRP ratio and KYNA/KYN ratio, were measured at baseline and after ECT sessions 2, 4, 6 and 8. RESULTS: Anhedonia responders had higher TRP levels (after ECT session 8) and lower KYNA levels (after ECT sessions 4 and 6) than non-responders (all p's < 0.05). Anhedonia remitters had a lower KYNA/KYN ratio (after ECT sessions 2, 6) and lower KYN/TRP ratio (after ECT sessions 8) compared to non-remitters (all p's < 0.05). The reduction in anhedonia scores after ECT session 2 were related to the reduction of KYN levels from baseline to ECT session 2 (r = 0.3, p = 0.049). TRP, KYN levels and KYN/TRP ratios predicted antianhedonic efficacy for ECT (TRP: β = 1.6, p = 0.029; KYN: β = -2.4, p = 0.033; KYN/TRP ratio: β = 1.9, p = 0.027). CONCLUSION: This preliminary study found that ECT treatment significantly improved anhedonia symptoms in TRD patients and this improvement was related to biomarker changes in the KYN pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electroconvulsive TherapyKynurenineDepressive Disorder, Treatment-ResistantAnhedoniaMajor Depressive DisorderHumansMaleFemaleTryptophanMiddle AgedKynurenic AcidAdultBiomarkersTreatment OutcomeAgedPsychiatric Status Rating Scales

Stichwörter der Autor:innen

AnhedoniaElectroconvulsive therapyKynurenineTreatment-resistant depression

Substanzen

KynurenineTryptophanKynurenic AcidBiomarkers

Autor:innen und Institutionen

  • The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China; Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical Universi…
  • Department of Psychiatry, University of Saskatchewan, Saskatoon, SK, Canada.
  • Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Centre for Cognitive and Brain Scie…

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Program key projects
  • Guangzhou Municipal Science and Technology Project
  • National Clinical Key Specialty Project Foundation
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Zeng, Q. B., Huang, X. B., Xu, R., Shang, D. W., Huang, S. Q., Huang, X., Yang, X. H., Balbuena, L., Xiang, Y. T., & Zheng, W. (2025). Kynurenine pathway metabolites predict antianhedonic effects of electroconvulsive therapy in patients with treatment-resistant depression. Journal of Affective Disorders, 379, 764-771. https://doi.org/10.1016/j.jad.2025.03.041

Vancouver

Zeng QB, Huang XB, Xu R, Shang DW, Huang SQ, Huang X, et al. Kynurenine pathway metabolites predict antianhedonic effects of electroconvulsive therapy in patients with treatment-resistant depression. Journal of Affective Disorders. 2025;379:764-771. doi:10.1016/j.jad.2025.03.041

BibTeX
@article{Zeng2025,
  author = {Zeng, Qing-Bin and Huang, Xing-Bing and Xu, Rui and Shang, De-Wei and Huang, Shan-Qing and Huang, Xiong and Yang, Xin-Hu and Balbuena, Lloyd and Xiang, Yu-Tao and Zheng, Wei},
  title = {Kynurenine pathway metabolites predict antianhedonic effects of electroconvulsive therapy in patients with treatment-resistant depression},
  journal = {Journal of Affective Disorders},
  year = {2025},
  volume = {379},
  pages = {764--771},
  doi = {10.1016/j.jad.2025.03.041}
}
Kostenlos starten →